Showing results (1-10 of 241) with videos related to

Sort By:
Pageof 25
Expert Review of Hematology|November 19, 2010
Suboptimal responses in chronic myeloid leukemia: milestones and mechanismsKimmo Porkka, Satu Mustjoki, Bengt Simonsson
Current Drug Targets|December 15, 2010
Interferon alpha for treatment of chronic myeloid leukemiaBengt Simonsson, Henrik Hjorth-Hansen, Ole Weis Bjerrum, et al.
European Journal of Haematology|July 28, 2010
Molecular monitoring and mutation analysis of patients with advanced phase CML and Ph+ ALL receiving dasatinibUlla Olsson-Strömberg, Monica Hermansson, Tuija Lundán, et al.
Plos One|January 31, 2017
Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid LeukemiaMohamed El Missiry, Henrik Hjorth-Hansen, Johan Richter, et al.
Blood|May 4, 2011
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS scoreJoerg Hasford, Michele Baccarani, Verena Hoffmann, et al.
British Journal of Haematology|April 25, 2009
Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemiaFranz Gruber, Satu Mustjoki, Kimmo Porkka
European Journal of Haematology|July 29, 2010
Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapyPeter Rohon, Kimmo Porkka, Satu Mustjoki
European Journal of Haematology|August 2, 2014
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)Henrik Hjorth-Hansen, Leif Stenke, Stina Söderlund, et al.
Leukemia Research|October 7, 2016
Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuliStina Söderlund, Lisa Christiansson, Inger Persson, et al.
European Journal of Haematology|December 31, 2013
Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular responsePerttu Koskenvesa, Anna Kreutzman, Peter Rohon, et al.
Pageof 25